GlassScriptPhysician profile
Muntarin Karim
NPI 1235794181
$1,609.57
in general payments reported to CMS, 2019-2025
13 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $245 · 2023: $477 · 2024: $695 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.95 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $403.85 | 2022-2024 | Lupkynis |
| Abbvie INC. | $350.31 | 2024-2025 | |
| Glaxosmithkline, LLC. | $265.05 | 2023 | Benlysta |
| Genzyme Corporation | $162.81 | 2023 | |
| Amgen INC. | $114.48 | 2024 | Otezla, Enbrel, Evenity |
| Radius Health, INC. | $90.91 | 2024 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $46.56 | 2024 | Saphnelo |
| Janssen Biotech, INC. | $44.75 | 2024 | Tremfya |
| Pfizer INC. | $34.33 | 2024 | |
| Lilly USA, LLC | $31.39 | 2024 | Taltz |
| Kiniksa Pharmaceuticals International, Plc | $27.73 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $21.84 | 2024 | Orencia |
| Ibsa Pharma INC. | $15.56 | 2024 | Tirosint, Flector, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muntarin Karim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.